secwatch.observer — SEC 8-K summary
======================================

Issuer:     SAB Biotherapeutics, Inc. (SABS)
CIK:        0001833214
Form:       8-K
Filed at:   2024-06-27T23:59:59+00:00
Accession:  0000950170-24-078622
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

SAB Biotherapeutics shareholders elect directors, approve equity plan amendment, ratify auditor at 2024 annual meeting
--------------------------------------------------------------------------------

- Shareholders elected Samuel J. Reich, Christine Hamilton, and Eddie J. Sullivan as Class III directors for three-year terms.
- Approved amendment to 2021 Omnibus Equity Incentive Plan, increasing share reserve by 3.9M to 5.5M shares.
- Ratified EisnerAmper LLP as independent registered public accounting firm for FY 2024.
- Voting results: For director elections, votes ranged from 4.89M to 5.15M with ~1.3M broker non-votes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1833214/000095017024078622/0000950170-24-078622-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1833214/000095017024078622/sabs-20240627.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-078622

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer